Skip to content


  • Oral presentation
  • Open Access

Neutralizing anti-Tat antibodies prolonged HAART interruption in vaccines in a prospective structured interruption study

  • Nathan Clumeck1,
  • Philippe Hermans1,
  • Daniel Zagury2,
  • Hélène Le Buanec2,
  • Arsène Burny3,
  • Bernard Bizzini2,
  • Bruce Gilliam4,
  • Robert Redfield4 and
  • Robert Gallo4
Retrovirology20063(Suppl 1):S15

Published: 21 December 2006


PlaceboInfectious DiseaseCancer ResearchCell ApoptosisEpidemiological Data

Anti-Tat therapeutic vaccination has been clinically investigated by different groups [14], given that 1) extracellular Tat protein induces T cell apoptosis and cellular immune suppression, 2) epidemiological data showed that LTNP exhibit high level of serum anti-Tat Ab, negatively correlated with p24 antigenemia, 3) in Tat immunized macaques, viremia decreased following SHIV challenge. Anti-Tat therapeutic vaccination using Tat Toxoid adjuvanted either with Seppic [1, 2] or with alum or DcChol (Aventis Pasteur) proved to be safe. A prospective structured treatment interruption study (STI) monitored according to EU guidelines was conducted at Hospital St-Pierre, Brussels (Pr. N. Clumeck) on 31 vaccinees who received a DcChol adjuvanted Tat Toxoid (n = 12), a DcChol placebo (n = 8) or non adjuvanted Tat toxoid (n = 11). The 2 year study follow-up showed that vaccinees developing high titer of Abs neutralizing Tat bioactivity prolonged HAART-interruption.

Authors’ Affiliations

Division of Infectious Diseases, CHU Saint-Pierre, Brussels, Belgium
Neovacs, S.A., Paris, France
Laboratory of Experimental Hematology, Bordet Institute, Brussels, Belgium
Institute of Human Virology, University of Maryland Biotechnology Center, Baltimore, USA


  1. Gringeri A, Santagostino E, Muca-Perja M, Mannucci PM, Zagury JF, Bizzini B, Lachgar A, Carcagno M, Rappaport J, Criscuolo M, Blattner W, Burny A, Gallo RC, Zagury D: Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients. J Hum Virol. 1988, 1: 293-298.Google Scholar
  2. Gringeri A, Santagostino E, Muca-Perja M, Le Buanec H, Bizzini B, Lachgar A, Zagury JF, Rappaport J, Burny A, Gallo RC, Zagury D: Tat toxoid as a component of a preventive vaccine in seronegative subjects. J Acquir Immune Defic Syndr Hum Retrovirol. 1999, 20: 371-375.View ArticlePubMedGoogle Scholar
  3. Caputo A, Gavioli R, Ensoli B: Recent advances in the development of HIV-1 Tat-based vaccines. Curr HIV Res. 2004, 2: 357-376. 10.2174/1570162043350986.View ArticlePubMedGoogle Scholar
  4. Calarota SA, Leandersson AC, Bratt G, Hinkula J, Klinman DM, Weinhold KJ, Sandstrom E, Wahren B: Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment. J Immunol. 1999, 163: 2330-2338.PubMedGoogle Scholar


© Clumeck et al; licensee BioMed Central Ltd. 2006

This article is published under license to BioMed Central Ltd.